Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VentriPoint Diagnostics Ltd VPTDF


Primary Symbol: V.VPT

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

Recent & Breaking News (TSXV:VPT)

Ventripoint Announces $500,000 Debenture Unit Private Placement

Marketwired August 1, 2013

Ventripoint Announces Closing of Private Placement

Marketwired July 29, 2013

University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal

Marketwired July 25, 2013

VentriPoint Announces Closing of Private Placement and Corporate Update

Marketwired June 24, 2013

VentriPoint Announces Closing of Private Placement and Corporate Update

Marketwired June 24, 2013

Ventripoint Announces New Vice-President of Sales and Marketing

Marketwired May 30, 2013

Ventripoint Announces New Vice-President of Sales and Marketing

Marketwired May 30, 2013

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

Marketwired May 23, 2013

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

Marketwired May 23, 2013

VentriPoint Announces Private Placements

Marketwired May 6, 2013

VentriPoint Announces Private Placements

Marketwired May 6, 2013

VentriPoint Receives Health Canada License for the NRV(TM) Application for Non-Specific Heart Disease

Marketwired April 30, 2013

VentriPoint Receives Health Canada License for the NRV(TM) Application for Non-Specific Heart Disease

Marketwired April 30, 2013

VentriPoint Receives Request for Clarification to 510 (k) Submission for Pulmonary Arterial Hypertension

Marketwired April 25, 2013

VentriPoint Receives Request for Clarification to 510 (k) Submission for Pulmonary Arterial Hypertension

Marketwired April 25, 2013

VentriPoint Announces Closing of Offering

Marketwired April 22, 2013

VentriPoint Receives CE Mark for Major Expansion of Its VMS(TM) Platform for Right Heart Analysis

Marketwired April 17, 2013

VentriPoint Announces First Closing of Offering And Issuance of Shares for Debt

Marketwired April 1, 2013

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

MarketWire Canada March 21, 2013

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

Marketwired March 21, 2013